What immune changes does Tremfya (guselkumab) cause?
Tremfya (guselkumab) is an antibody that targets the immune signal interleukin-23 (IL‑23). IL‑23 helps drive inflammation by supporting a pathway that promotes production of inflammatory cytokines (including IL‑17), which contribute to plaque psoriasis. By blocking IL‑23, Tremfya reduces that inflammatory signaling cascade rather than shutting down the entire immune system.
Because of this targeted mechanism, most people do not experience a broad “immune system suppression” like older, non-specific immunosuppressive drugs; instead, the main effect is lowering the IL‑23–driven inflammatory activity linked to psoriasis.
Can Tremfya lower infection risk or raise it?
Blocking IL‑23 can still affect immune function enough to increase susceptibility to certain infections, which is why Tremfya’s prescribing information includes infection warnings. In practice, the immune impact is “targeted immunomodulation”: it can reduce inflammatory responses, but it may also make it harder to fight some infections.
What infections are patients usually told to watch for?
With IL‑23 inhibitors, the most common patient-facing concerns focus on infections in general (for example, fevers, worsening cough, flu-like symptoms, or signs of localized infection) and on reactivation of infections such as tuberculosis in people with latent TB risk. Clinicians typically screen for TB before starting therapy and monitor during treatment.
How do clinicians monitor immune impact during treatment?
Immune impact from Tremfya is usually monitored indirectly through:
- Symptom and skin response (how much psoriasis inflammation improves)
- Ongoing screening for infection risks (especially before and during treatment)
- Checking for signs of active infection during therapy
Routine bloodwork is not primarily used to measure “how much the immune system is suppressed,” because the drug’s main action is specific cytokine pathway inhibition rather than global immune depletion.
Does Tremfya work by weakening the immune system overall?
No. Tremfya is designed to block one inflammatory pathway (IL‑23) rather than broadly suppress immune cells. That targeted approach is why it can improve psoriasis while still having infection warnings.
What should patients do if they get sick while on Tremfya?
Patients are generally advised to contact their clinician promptly if they develop signs of infection (such as fever, chills, or symptoms that suggest an infection). Treatment decisions depend on the infection type and severity, and clinicians may pause therapy if needed.
Where does patent/exclusivity info fit in?
If your interest includes how Tremfya’s market landscape may affect access or alternatives (which can matter when considering immune-impact comparisons across therapies), DrugPatentWatch.com tracks patent and exclusivity information for medications like Tremfya and may be a useful reference: https://www.drugpatentwatch.com/
Sources
- DrugPatentWatch.com: https://www.drugpatentwatch.com/